The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-Intensive (DI) Chemotherapy (CT) Prolongs Event-Free Survival (EFS) for Very Young Children with Ependymoma (EP). Results of Pediatric Oncology Group (POG) Study 9233.
 
Masanori Terashima
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Otsuka (Inst); Yakult Honsha (Inst)
 
Kazumasa Fujitani
No Relationships to Disclose
 
Masahiko Ando
No Relationships to Disclose
 
Kentaro Sakamaki
No Relationships to Disclose
 
Ryohei Kawabata
No Relationships to Disclose
 
Yuichi Ito
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Masato Kondo
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Olympus; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - abbott Japan (Inst); Abbvie (Inst); Ajinomoto (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Maruho (Inst); Merck (Inst); Mitsubishi Tanabe Pharma (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst); Yoshindo (Inst)
 
Masahide Kaji
No Relationships to Disclose
 
Yoshio Oka
No Relationships to Disclose
 
Hiroshi Imamura
No Relationships to Disclose
 
Junji Kawada
No Relationships to Disclose
 
Akinori Takagane
No Relationships to Disclose
 
Hideaki Shimada
No Relationships to Disclose
 
Yutaka Tanizawa
No Relationships to Disclose
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Morita
No Relationships to Disclose
 
Motoki Ninomiya
No Relationships to Disclose
 
Kazuhiro Yoshida
Honoraria - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha